Eszopiclone


Generic Medicine Info
Administration
Should be taken on an empty stomach. Take immediately before going to bed. Avoid taking after a heavy meal.
Special Precautions
Patient w/ history of drug dependence, resp compromise (e.g. COPD, sleep apnoea), depression, diseases or conditions that could affect metabolism or haemodynamic responses. Avoid abrupt withdrawal. Severe hepatic impairment. Elderly and debilitated patients. Pregnancy and lactation. Patient Counselling May impair ability to drive, operate machinery or other activities that require alertness. Take the medication when there is at least 7-8 hr of sleep. Monitoring Parameters Monitor patients w/ history of drug addiction, abuse, tolerance or dependence. Monitor patients for abnormal thinking or behaviour.
Adverse Reactions
CNS depressant effects (e.g. impaired alertness and motor coordination), abnormal thinking, behavioural changes (e.g. hallucinations), amnesia and other neuropsychiatric symptoms, exacerbation of depression, suicidal thinking, complex behaviours (e.g. "sleep-driving"), unpleasant taste, headache, somnolence, resp infection, dizziness, dry mouth, dyspepsia, nausea, nervousness, rash, viral infection, anxiety, vomiting, confusion, decreased libido, dysmenorrhoea, gynecomastia, dysosmia.
Potentially Fatal: Anaphylaxis and angioedema.
Drug Interactions
Additive effects w/ CNS depressants (e.g. benzodiazepine, opioids, TCAs). Decreased exposure and effect w/ CYP3A4 inducers (e.g. rifampicin). Increased exposure and effect w/ CYP3A4 inhibitors (e.g. ketoconazole).
CIMS Class
Hypnotics & Sedatives
ATC Classification
N05CF04 - eszopiclone ; Belongs to the class of benzodiazepine related drugs. Used as hypnotics and sedatives.
Disclaimer: This information is independently developed by CIMS based on eszopiclone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in